NASC (Nascent Pharma Holdings) Cyclically Adjusted PS Ratio: (As of Jul. 06, 2026)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.02
View Full Analysis

What is Nascent Pharma Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nascent Pharma Holdings  (OTCPK:NASC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nascent Pharma Holdings Cyclically Adjusted PS Ratio Related Terms


Nascent Pharma Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Cyclically Adjusted PS Ratio Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.32 1.75 0.28 0.01

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.00 0.00

NASC vs ALID, CPMD, PLSH: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Pharma Holdings Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Cyclically Adjusted PS Ratio falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nascent Pharma Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Nascent Pharma Holdings's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0/315.3010*315.3010
=0.000

Current CPI (Sep. 2024) = 315.3010.

Nascent Pharma Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.184 234.812 0.247
201503 0.714 236.119 0.953
201506 0.560 238.638 0.740
201509 0.358 237.945 0.474
201512 0.615 236.525 0.820
201603 0.688 238.132 0.911
201606 0.781 241.018 1.022
201609 0.750 241.428 0.979
201612 0.719 241.432 0.939
201703 0.316 243.801 0.409
201706 0.419 244.955 0.539
201709 0.344 246.819 0.439
201712 1.267 246.524 1.620
201803 0.864 249.554 1.092
201806 1.833 251.989 2.294
201809 1.698 252.439 2.121
201812 2.422 251.233 3.040
201903 3.172 254.202 3.934
201906 3.987 256.143 4.908
201909 3.122 256.759 3.834
201912 3.134 256.974 3.845
202003 2.457 258.115 3.001
202006 0.820 257.797 1.003
202009 2.040 260.280 2.471
202012 1.466 260.474 1.775
202103 0.504 264.877 0.600
202106 0.258 271.696 0.299
202109 0.954 274.310 1.097
202112 0.700 278.802 0.792
202203 0.590 287.504 0.647
202206 0.377 296.311 0.401
202209 0.828 296.808 0.880
202212 0.161 296.797 0.171
202303 0.192 301.836 0.201
202306 0.076 305.109 0.079
202309 0.036 307.789 0.037
202312 0.012 306.746 0.012
202403 0.010 312.332 0.010
202406 0.005 314.175 0.005
202409 0.000 315.301 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price